Merck and Moderna reported median five-year follow-up results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating intismeran autogene plus Keytruda in high-risk stage III/IV melanoma patients. The combination reduced the risk of recurrence or death by 49% versus Keytruda alone, matching the benefit seen at the three-year analysis. Safety findings remained consistent with earlier reports, with no new adverse signals. The data were derived from a cohort of 157 patients who underwent complete surgical resection, underscoring the long-term durability of this individualized mRNA approach.

These results bolster Merck’s lead in immuno-oncology by integrating personalized neoantigen technology into its blockbuster Keytruda platform. With approximately 112,000 new U.S. melanoma cases projected in 2026, analysts at Jefferies estimate peak annual sales for this adjuvant vaccine could reach multi-billion-dollar levels if priced similarly to Keytruda. Merck’s collaboration structure calls for shared development costs and profits, enhancing its long-term growth potential as it seeks to offset patent expirations on other key drugs.

Building on these durable melanoma findings, Merck and Moderna have fully enrolled a Phase 3 adjuvant melanoma study (INTerpath-001) and are conducting multiple Phase 3 trials in non-small cell lung cancer, alongside Phase 2 programs in renal cell carcinoma and bladder cancer. Morgan Stanley recently reiterated a Neutral rating on Merck’s stock, citing the importance of these readouts for near-term value creation. While average analyst price targets remain below current trading levels, consensus views the five-year data as a critical validation of Merck’s strategy to expand its immuno-oncology portfolio beyond checkpoint inhibitors.